Back grey_arrow_rt.gif
 
COVID-19
 
Coronavirus / Coronavirus & HIV
 
null.gif
 
 
  1. CROI: COVID-19 Omicron infection and severe outcomes in HIV and matched non-HIV cohorts in Ontario, Canada - (03/27/24)
     
  2. CROI: Effects of Pitavastatin on COVID-19 Incidence and Seriousness among People with HIV - (03/20/24)
     
  3. CROI: Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study - (03/15/24)
     
  4. CROI: Hospital and Death Rate Almost Twice Higher After SARS-CoV-2 in Unvaccinated - Mark Mascolini (03/11/24)
     
  5. CROI: COVID Incidence and Severity in Persons with Reinfection vs Post-vaccination Breakthrough Infection....>65, comorbidities protected more - (03/11/24)
     
  6. NIH to bolster RECOVER Long COVID research efforts through infusion of $515 million - (02/16/24)
     
  7. SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020-2022 - (01/29/24)
     
  8. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2 - (01/15/24)
     
  9. Long COVID: major findings, mechanisms and recommendations - (01/15/24)
     
  10. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection - (12/28/23)
     
  11. Long COVID in people living with HIV - (12/28/23)
     
  12. NATAP/LongCOVIDWk: Current treatments for Long COVID - (12/28/23)
     
  13. Paxlovid Reduced Long COVID Conditions - (12/28/23)
     
  14. Long COVID Clinics by State - (12/28/23)
     
  15. NYC Post COVID Care Clinics, Rehabs - (12/28/23)
     
  16. HIV Infection is Associated with Higher Risk of Post-Acute Sequelae of SARS-CoV-2 (PASC) However Vaccination is Protective - (12/28/23)
     
  17. CDC study: People with HIV have elevated COVID reinfection rate - (12/28/23)
     
  18. Paxlovid Treatment for Long COVID Trial Ongoing - (12/28/23)
     
  19. Long COVID in the United States - (12/21/23)
     
  20. Long COVID in the United States - (12/21/23)
     
  21. AASLD: Liver Damage & COVID Vaccines - (11/20/23)
     
  22. EACS: Impact of directly acting-antivirals and behaviour change on HCV micro-elimination in MSM due to the COVID 19 pandemic in Germany - Results from the NoCo cohort - (11/8/23)
     
  23. EACS: COVID-19 Associated with 35% Increased Risk for Major Cardiovascular events in PWH During Subsequent Yea - (11/06/23)
     
  24. IDWeek: Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Adults - IVY Network, 20 U.S. States, September 8, 2022-May 31, 2023 - (10/26/23)
     
  25. IDWeek: Fully vaccinated individuals with immunocompromised conditions are still at increased risk of severe COVID-19 outcomes from the Omicron variant: initial results from INFORM, a retrospective health database observational study in England - (10/26/23)
     
  26. IDWeek: Use of Paxlovid for treatment of acute COVID-19 and occurrence of Post-COVID Conditions among adolescents and adults at high-risk for severe COVID-19, April 1 - December 31, 2022 - (10/26/23)
     
  27. IDWeek: A Systematic Literature Review Evaluating Real-World Use of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Death - (10/26/23)
     
  28. IDWeek: Molnupiravir and Nirmatrelvir/ritonavir effectiveness in reducing the risk for COVID-19 disease progression and death - (10/25/23)
     
  29. IDWeek: NIRMATRELVIR/RITONAVIR VERSUS PLACEBO IN UNVACCINATED AND VACCINATED HIGH-RISK PATIENTS - (10/25/23)
     
  30. IDWeek: Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression - (10/25/23)
     
  31. IDWeek: Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment For COVID-19 - (10/25/23)
     
  32. IDWeek: Drug-Drug Interaction Profiling of Obeldesivir, a Promising Oral Treatment for COVID-19 - (10/25/23)
     
  33. CDC: Long COVID in Adults: United States, 2022 - (09/26/23)
     
  34. Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential - (09/24/23)
     
  35. Pharmacokinetics, Safety, and Tolerability of Obeldesivir (OBV; GS-5245) in Healthy Participants - (09/24/23)
     
  36. IAS: Long COVID and HIV: Scientific and Biologic Intersections - (08/14/23)
     
  37. COVID at CDC Conference: Update on Rapid Assessment of SARS-CoV-2 Transmission at 2023 EIS Conference - (06/01/23)
     
  38. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022 - (05/30/23)
     
  39. Perceived Cognitive Deficits in Patients With Symptomatic SARS-CoV-2 and Their Association With Post-COVID-19 Condition - (05/22/23)
     
  40. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies - (05/22/23)
     
  41. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong - (05/22/23)
     
  42. COVID-19 Vaccination and Hospitalization Among Persons Living With Diagnosed HIV in New York State - (05/22/23)
     
  43. CROI: COVID at CROI 2023 - (03/22/23)
     
  44. CROI: Pharmacokinetics Inform Remdesivir Dosing for Patients With Severe Renal Impairment - (03/22/23)
     
  45. CROI: MICROBIOME-DERIVED METABOLITES ARE POWERFUL BIOMARKERS FOR ANAL CANCER PREVENTION - (03/22/23)
     
  46. VV116, GS-5245 for COVID - (03/24/23)
     
  47. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition - (03/24/23)
     
  48. CROI: REMDESIVIR REDUCES MORTALITY IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED FOR COVID-19 - (03/22/23)
     
  49. CROI: Remdesivir Retains Potent Antiviral Activity Against SARS-CoV-2 Variants of Concern - (03/22/23)
     
  50. CROI: Safety and Efficacy of Inhaled Interferon-β1a
    (SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19     - (03/14/23)
     
  51. CROI: Ensitrelvir for mild-to-moderate COVID-19: Phase 3 part of Phase 2/3 study - (03/14/23)
     
  52. Long COVID Incidence CDC 15%-20% - (03/14/23)
     
  53. Metformin Reduced Long COVID Incidence by 43% - (03/07/23)
     
  54. CROI: TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV - (03/05/23)
     
  55. CROI: OLFACTORY PERFORMANCE IN POST MILD-TO-MODERATE ACUTE COVID-19 ACROSS 2 YEARS - (03/05/23)
     
  56. CROI: TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV - (03/05/23)
     
  57. CROI: Post Covid Cognitive Impairment Neuro imaging Abnormalities on MRI- A Potential Biomarker - (03/05/23)
     
  58. CROI: NIRMATRELVIR USE AND HOSPITALIZATIONS OR DEATH IN INDIVIDUALS WITH COVID-19 - (03/05/23)
     
  59. CROI: Cognitive, Motor, & Negative Valence Systems in Neurologic PASC: A Preliminary Study - (03/02/23)
     
  60. CROI: Intervention efficacy on COVID-19 testing and vaccination in people who inject drugs - Mark Mascolini (03/02/23)
     
  61. CROI: Travel Strictures in Canada Slowed SARS-Cov-2 Variant Arrivals-Briefly - Mark Mascolini - (03/02/23)
     
  62. CROI: COVID-19 bivalent booster effectiveness in people with and without immune dysfunction - Mark Mascolini (03/01/23)
     
  63. CROI: COVID in US Made HIV Diagnoses Plunge in 2020-But Why? - (02/28/23)
     
  64. Lingering symptoms common after COVID hospitalization - (02/14/23)
     
  65. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2 - (02/13/23)
     
  66. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US - CD4 <350 Increased Risk for Post Vaccine Severe Breakthrough - (01/13/23)
     
  67. Long COVID Prevalence Outcomes - Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021 - (01/07/23)
     
  68. Effects of the pandemic on HIV service provision - (01/07/23)
     
  69. Most Long COVID Cases Started With Mild Symptoms: Study - (01/07/23)
     
  70. NY sees a 30% spike in COVID deaths in December, most since early 2022 - (01/07/23)
     
  71. POTS, a debilitating heart condition is linked to COVID and to a lesser degree, vaccines - (01/02/23)
     
  72. New Variant in NY - Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster - (12/29/22)
     
  73. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial - (12/29/22)
     
  74. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster - (12/22/22)
     
  75. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients - (12/15/22)
     
  76. AASLD: Cirrhosis Linked to More Than Doubled Odds of Severe COVID - Mark Mascolini (11/10/22)
     
  77. ID Week: Ivermectin, Fluticasone, Fluvoxamine Can't Beat Placebo for Mild/Moderate COVID - Mark Mascolini (10/25/22)
     
  78. ID Week: Postacute COVID Less Common in US Youth Than Reported Earlier - Mark Mascolini (10/25/22)
     
  79. ID Week: Age, Immune Conditions, Comorbidities Drive Severe COVID Risk After Vaccination - Mark Mascolini (10/25/22)
     
  80. ID Week: In Big US HIV Group, Hispanics, Blacks, Southerners, Overweight Run Higher COVID Risk - Mark Mascolini (10/25/22)
     
  81. ID Week: Impaired Fitness Peaks 1 Month After COVID Onset but May Persist 12 Months - Mark Mascolini (10/25/22)
     
  82. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial - (10/11/22)
     
  83. Dying at Home Due to Coronavirus Disease 2019 - (09/14/22)
     
  84. Paxlovid Outcomes during the Omicron Surge in Israel- Young vs Old - (09/09/22)
     
  85. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients - (09/06/22)
     
  86. Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine - (08/25/22)
     
  87. Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022 - (08/16/22)
     
  88. Pfizer and BioNTech Announce Omicron-Adapted (BA.5) COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron - (07/14/22)
     
  89. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study - (07/07/22)
     
  90. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers - (07/07/22)
     
  91. FDA recommends including omicron subvariants BA.4 and BA.5 in fall Covid boosters - (07/07/22)
     
  92. Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5 - (07/07/22)
     
  93. Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron - (07/07/22)
     
  94. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study - (07/07/22)
     
  95. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers - (07/07/22)
     
  96. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States - (06/13/22)
     
  97. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 - (06/13/22)
     
  98. Greater risk of post-vaccination breakthrough severe COVID-19 illness in people with HIV and CD4 <350 - (06/13/22)
     
  99. COVID 5th Wave So Africa - Boosters "Stay Up-To-date" White House Briefing - (06/01/22)
     
  100. Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors - (06/01/22)
     
  101. Interferon therapy shows striking results against COVID-19 - (05/31/22)
     
  102. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial - (05/31/22)
     
  103. Peginterferon Lambda Single Injection for Newly Diagnosed COVID - TOGETHER Phase 3 Study - (05/31/22)
     
  104. Interferon [lambda] therapy shows striking results against COVID-19 - (05/31/22)
     
  105. Biden Administration Announces Launch of First COVID Federally-Supported Test to Treat Site - (05/26/22)
     
  106. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapies - (05/24/22)
     
  107. Molnupiravir for the Treatment of COVID-19 in Immunocompromised Patients: Efficacy, Safety, and Virology Results from the Phase 3 MOVe-OUT Trial - (05/24/22)
     
  108. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples - (04/20/22)
     
  109. Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant - (04/08/22)
     
  110. NYC DOH COVID PrEP, Treatment - Evusheld for pre-exposure prophylaxis - (04/08/22)
     
  111. Therapeutic Management of Nonhospitalized Adults With COVID-19 - (04/06/22)
     
  112. SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center - (04/05/22)
     
  113. Long- Covid in PLWH & Immune Responses in PLWH Recovering From COVID Prior to Vaccine Availability - (03/15/22)
     
  114. CROI: NIH Launches Clinical Trial of Three mRNA HIV Vaccines - (03/14/22)
     
  115. Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose - (03/08/22)
     
  116. Booster Waning Benefit vs Omicron UK Study NEJM just published - Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant - (03/04/22)
     
  117. CROI: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants (02/24/22)
     
  118. CROI: More Adverse Birth Outcomes With COVID Plus HIV in Botswana - Mark Mascolini (02/22/22)
     
  119. CROI: Post-COVID19 Quality of Life: Low Satisfaction With Physical and Mental Health Status - (02/22/22)
     
  120. CROI: SARS-CoV-2 Prevalence Similar in Adults and Children in 15-Site US Study - Mark Mascolini (02/22/22)
     
  121. CROI: The Impact of COVID-19 on Adverse Birth Outcomes in Botswana by HIV Status - (02/20/22)
     
  122. CROI: DURABILITY OF SARS-COV-2 mRNA VACCINE IMMUNE RESPONSE IN PLWH WITH ADVANCED DISEASE - (02/18/22)
     
  123. CROI: Immunogenicity and reactogenicity to COVID-19 mRNA vaccine additional dose in PLWH - (02/18/22)
     
  124. CROI: SARS-CoV-2 Vaccine Immunogenicity in PLWH in The Netherlands & age, CD4, HIV viral load effects - (02/18/22)
     
  125. CROI: Sotrovimab mAb Limits Progression to Severe COVID Regardless of Serostatus - Mark Mascolini (02/18/22)
     
  126. CROI: Intramuscular Sotrovimab Noninferior to IV for Mild/Moderate COVID - Mark Mascolini (02/18/22)
     
  127. CROI: Dual Monoclonal Antibody Cuts COVID Risk in 8-Month Placebo Trial - Mark Mascolini (02/16/22)
     
  128. CROI: COVID-19 BOOSTER VACCINE EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - in reducing breakthrough, duration of benefit (02/16/22)
     
  129. CROI: Big Drops in HIV/STI Testing (But Sometimes Not Diagnoses) When COVID Arrived - Mark Mascolini (02/16/22)
     
  130. POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION - (02/16/22)
     
  131. CROI: COVID Pushes USA Farther Off Course to Meet HCV Elimination Goals - Mark Mascolini (02/17/22)
     
  132. CROI: Asymptomatic SARS-CoV-2 Infection is Extremely Common among People with HIV (02/16/22)
     
  133. CROI: Long COVID Definition - POST-ACUTE SEQUELAE OF SARS-COV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT (02/16/22)
     
  134. CROI: COVID Symptoms Reported Lasting Longer in US Than South Africa, Peru - Mark Mascolini (02/16/22)
     
  135. CROI: Long COVID Definition - Cardiac Rhythm Upsets, Diabetes, GU Symptoms Emerge as Persistent COVID Problems (02/15/22)
     
  136. CROI: Long COVID, Post Acute - Half of COVID Cohort Has Heart/Lung Symptoms 7 Months After Acute Infection - Mark Mascolini (02/15/22)
     
  137. CROI: COVID Vax More Likely in Older, Heavier Men (vs Women) in Global HIV Trial - Mark Mascolini (02/14/22)
     
  138. CROI: COVID mRNA Vaccines Appear to Protect Against Infection Transmission - Mark Mascolini (02/14/22)
     
  139. CROI: COVID Vax Booster Cuts Breakthrough Infections, Hospital Use, Death - Mark Mascolini (02/14/22)
     
  140. CROI: Post-Acute Long COVID: Lower Heart Rates During Exercise Point to Autonomic Dysfunction Causing Symptoms - Mark Mascolini (02/14/22)
     
  141. CROI: Impact of the COVID-19 Pandemic on HIV Outpatient Care and Viral Suppression in NYC - (02/14/22)
     
  142. Long-term cardiovascular outcomes of COVID-19 - (02/13/22)
     
  143. CROI: Impact of COVID outbreak on prevention and care for HIV and other STI's at a large hospital - (02/13/22)
     
  144. CROI: SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH - (02/13/22)
     
  145. A New Class of Antiviral Therapy Could Treat COVID-19 - (02/08/22)
     
  146. PLWH in NYC-COVID Vaccinations Disparities - (02/08/22)
     
  147. Long-Haul COVID Cases Could Spike after Latest Wave - (02/05/22)
     
  148. Protection by 4th dose of BNT162b2 against Omicron in Israel - (02/04/22)
     
  149. NYS Guidelines COVID Oral & Monoclonal Antibodies Treatments Eligibility - (01/18/22)
     
  150. Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System - (01/12/22)
     
  151. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data - (01/03/22)
     
  152. More evidence for worse COVID-19 outcomes in people with HIV - (01/03/22)
     
  153. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US - (12/29/21)
     
  154. Pfizer COVID Protease & DDIs with HIV ARTs - (12/28/21)
     
  155. Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment - (12/23/21)
     
  156. Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 - (12/23/21)
     
  157. COVID-19 Vaccination Rates in a Global HIV Cohort - (12/13/21)
     
  158. SARS-CoV-2 Infection Among People Living With HIV Compared With People Without HIV: Survey Results From the MACS-WIHS Combined Cohort Study - (12/10/21)
     
  159. Safety & Efficacy of SARS-CoV-2 Monoclonal Neutralizing Anibodies BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients - (12/03/21)
     
  160. Remdesivir For the Treatment of High-Risk Non-Hospitalized Individuals with COVID-19: A Randomized, Double, Blind, Placebo-Controlled Trial PINETREE Study -RDV for 3 day 87% reduction in hospitalization, there were no deaths in either arm - (12/03/21)
     
  161. AASLD: Worse Antibody and Cellular Response to SARS-CoV-2 Vax With Cirrhosis - Mark Mascolini (11/17/21)
     
  162. AASLD: Persistent COVID Symptoms, Weight Gain, Alcohol Use With Long COVID and Chronic Liver Disease - Mark Mascolini - (11/15/21)
     
  163. EACS: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study - (11/06/21)
     
  164. EACS: People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV-2 infection SARS-CoV-2 Risk No Higher With Well-Controlled HIV Than in HIV-Negatives - Mark Mascolini (11/06/21)
     
  165. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data - (10/20/21)
     
  166. Rates of COVID-19 Cases and Deaths by Vaccination Status - (10/15/21)
     
  167. mRNA HIV Vaccine Study
    A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)     - (10/07/21)
     
  168. IDWeek: Racial and Ethnic Disparities in COVID-19 Incidence among Persons with HIV in a Multisite-Cohort - (10/05/21)
     
  169. IDWeek: Lower SARS-CoV-2 IgG and Surrogate Virus Neutralization Titers Post-mRNA Vaccination among People Living with HIV - (10/05/21)
     
  170. Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study - (10/04/21)
     
  171. Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S (J&J vaccine) Vaccination - (10/04/21)
     
  172. IDWeek: Long-term clinical outcomes following SARS-CoV-2 infection include persistent symptoms and cardiovascular disease beyond 3 months post-infection - (10/03/21)
     
  173. IDWeek: Monoclonal Regdanvimab Cuts COVID Progression Risk in Placebo Trial - Mark Mascolini (10/03/21)
     
  174. IDWeek: CHARACTERIZATION OF HEAVILY TREATMENT-EXPERIENCED HIV-1-INFECTED CLINICAL TRIAL PARTICIPANTS INFECTED WITH SARS-COV-2 COVID-19: FOSTEMSAVIR BRIGHTE PHASE 3 CLINICAL TRIAL - (10/03/21)
     
  175. IDWeek: Treatment with molnupiravir in the MOVe-In and MOVe-Out clinical trials results in an increase in transition mutations across the SARS-CoV-2 genome - (09/30/21)
     
  176. IDWeek: Use of immune-viral dynamics modeling to understand molnupiravir drug effect for COVID-19 - (09/30/21)
     
  177. IDWeek: Clinical Characteristics of Patients Living with HIV Hospitalized for COVID-19 - PLWH have Higher Mortality Rate - (09/30/21)
     
  178. IDWeek: COVID Brings Drops in HIV Care Visits, Viral Load Measures, and ART Stops - Mark Mascolini (09/30/21)
     
  179. IDWeek: Remdesivir Linked to Viral Clearance Only in Certain Subsets - Mark Mascolini (09/30/21)
     
  180. AGE: Factors influencing psychological distress during the COVID-19 pandemic in people aging with HIV - (09/27/21)
     
  181. AGE: COVID Vaccine Effectivity in Aging & HIV Populations - (09/27/21)
     
  182. Second dose of Johnson & Johnson vaccine increases protection against covid-19, maker says - (09/22/21)
     
  183. Intl Wrkshp Clin Pharm: Drug-Drug Interaction Risk High With COVID Meds in Hospital - Mark Mascolini - (09/20/21)
     
    184. Intl Wrkshp Clin Pharm: New Oral Ribonucleoside Optimal at 800 mg Twice Daily vs SARS-CoV-2 - Mark Mascolini - (09/20/21)
     
    Intl Wrkshp Clin Pharm: Phase 1 Trial Suggests Antidiarrheal Nitazoxanide Dose for COVID - Mark Mascolini - (09/20/21)
     
  184. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study - (09/20/21)
     
  185. Covid-19 vaccine tracker: the global race to vaccinate - (09/17/21)
     
  186. IAS: Anxiety and Alcohol Consumption in the Miami Adult Studies on HIV (MASH) Cohort During the COVID-19 Pandemic - (09/01/21)
     
  187. Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1 - (08/24/21)
     
  188. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine - FDA Grants Full Approval - (08/24/21)
     
  189. HIV+ Study of Vaccine Response in Immunocompromised - Immunocompromised Response to COVID-19 Vaccination - (08/21/21)
     
  190. mRNA HIV Vaccine Trials Begin-Moderna - (08/21/21)
     
  191. COVID-Molnupiravir Activity/Safety
     
    β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells     - (08/13/21)
     
  192. HIV infection prevalence significantly intersects with COVID-19 infection at the area-level - (08/13/21)
     
  193. ACIP Aug 13 slides Immunocompromsed: Evidence to Recommendation Framework: An Additional Dose of mRNA COVID-19 Vaccine Following a Primary Series in Immunocompromised People - (08/13/21)
     
  194. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study - (08/08/21)
     
  195. Safety and Antibody Response to Two-Dose SARS-CoV-2 messenger RNA Vaccination in Persons with HIV - (08/05/21)
     
  196. FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19 - (08/05/21)
     
  197. FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab) - (08/05/21)
     
  198. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study - (09/17/20)
     
  199. Coronavirus Disease 2019 (COVID-19) Infection Among People With Human Immunodeficiency Virus in New York City: A Population-Level Analysis of Linked Surveillance Data - Commentary & paper 50% Higher COVID Deaths, hospitalizations & ICU due to COVID for PLWH vs HIV-Neg in NYC - (07/22/21)
     
  200. WHO warns that HIV infection increases risk of severe and critical COVID-19 - (07/15/21)
     
  201. EASL: The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry - (07/12/21)
     
  202. EASL: Liver Impairment With COVID-19 Tied to More Severe Coronavirus Disease - Mark Mascolini (06/26/21)
     
  203. EASL: Chronic liver disease and risk of mortality after COVID-19: a national, retrospective, cohort study for 2020 - Mark Mascolini (06/24/21)
     
  204. EASL: Impact of the COVID-19 Pandemic on Hepatitis C Virus Screening in Drug Treatment Settings in England and Implications for Future Testing Protocols - (06/23/21)
     
  205. EASL: Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress - (06/23/21)
     
  206. EASL: COVID Impact on Global Liver Disease - press releases from EASL 2021 EASL press releases - (06/23/21)
     
  207. Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial - (06/15/21)
     
  208. Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine - (06/15/21)
     
  209. Johnson & Johnson COVID-19 Vaccine Induces Strong T-Cell Response To Variants New Evidence Suggests COVID-19 Vaccines Remain Effective Against Variants - (06/10/21)
     
  210. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study - (06/05/21)
     
  211. Clinical features and outcomes of COVID-19 among people living with HIV in the United States: A multicenter study from a large global health research network (TriNetX) - PWH had higher rates of poor COVID outcomes - (06/05/21)
     
  212. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients - (05/26/21)
     
  213. CDC - Interim Estilates of Vaccine effectiveness in Preventing SARS-CoV-2 Infection - (04/7/21)
     
  214. CROI: REMDESIVIR VERSUS STANDARD OF CARE FOR SEVERE COVID-19 - (04/05/21)
     
  215. CROI: ACUTE KIDNEY INJURY IN PATIENTS WITH MODERATE COVID-19 TREATED WITH RDV VERSUS SoC - (04/05/21)
     
  216. CROI: TREATMENT AND OUTCOMES OF COVID-19 IN THE US: ARE THEY DIFFERENT ACCORDING TO RACE? - (04/05/21)
     
  217. CROI: SAFETY AND EFFICACY OF REMDESIVIR IN A PEDIATRIC COVID-19 POPULATION - (04/05/21)
     
  218. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques...."prevents infection" - (04/05/21)
     
  219. Prevents COVID Infection ? - CDC Real-World Study Confirms Protective Benefits of mRNA COVID-19 Vaccines - (03/31/21)
     
  220. AstraZeneca's Covid-19 Vaccine Is Reported to Be 79% Effective in U.S. Study - (03/04/21)
     
  221. CROI: COVID & HIV - Antiviral Molnupiravir, monoclonal antibody combinations, Convalesecent Plasma - (03/19/21)
     
  222. CROI: CROI 2021 - Complications: HIV, COVID - (03/19/21)
     
  223. CROI: PREVALENCE AND FACTORS ASSOCIATED WITH SARS-CoV-2 ANTIBODIES IN A SPANISH HIV COHORT - (03/16/21)
     
  224. CROI: COVID-19 IN HOSPITALIZED HIV-POSITIVE AND HIV-NEGATIVE PATIENTS: A MATCHED STUDY - (03/16/21)
     
  225. CROI: Dual mAb Prevents Symptomatic COVID-19 in Household-Exposed Group: Interim Results of Placebo-Controlled Trial - Mark Mascolini (03/15/21)
     
  226. CROI: RISK FACTORS FOR HOSPITALIZATION IN PEOPLE WITH HIV AND COVID-19 - (03/15/21)
     
  227. CROI: BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH- RISK AMBULATORY PATIENTS - (03/10/21)
     
  228. CROI: Convalescent Plasma Has No Effect on Survival or Disease Course With Severe COVID-19 - Mark Mascolini (03/10/21)
     
  229. CROI: mAb Bamlanivimab Lowers Odds of SARS-CoV-2 and Symptomatic COVID-19 in Nursing Facilities - Mark Mascolini - (03/10/21)
     
  230. CROI: BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING - (03/10/21)
     
  231. CROI: REDUCTION IN INFECTIOUS SARS-CoV-2 IN TREATMENT STUDY OF COVID-19 WITH MOLNUPIRAVIR - (03/10/21)
     
  232. CROI: COVID Virus Can Linger in Gut a Half-Year After Symptoms Clear - Mark Mascolini - (03/10/21)
     
  233. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York - (03/04/21)
     
  234. Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee - (03/04/21)
     
  235. Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate - (02/22/21)
     
  236. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial - (02/20/21)
     
  237. Covid vaccine shots for the next several years - (02/20/21)
     
  238. Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial - (02/12/21)
     
  239. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera - (02/10/21)
     
  240. Evolution of antibody immunity to SARS-CoV-2. COVIS reservoirs as in HIV ? - (02/06/21)
     
  241. NYS to open up COVID-19 vaccine to people with comorbidities starting February 15 - (02/06/21)
     
  242. Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate - (02/06/21)
     
  243. Johnson & Johnson submits application for Covid-19 vaccine to FDA - (02/06/21)
     
  244. AstraZeneca Vaccine May Cut Transmission of Virus - (02/05/21)
     
  245. In Vitro Studies Demonstrate Pfizer and BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants - (02/05/21)
     
  246. Pfizer's COVID-19 vaccine less effective against South African variant - (02/05/21)
     
  247. AstraZeneca, Oxford expect 'next generation' COVID-19 vaccine to tackle variants by autumn - executive - (02/05/21)
     
  248. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State - (02/05/21)
     
  249. Young and middle-aged adults responsible for most COVID spread - (02/05/21)
     
  250. Worrisome coronavirus mutation seen in U.K. variant and in some U.S. samples - (02/05/21)
     
  251. GSK and CureVac to develop next generation mRNA COVID-19 vaccines - (02/04/21)
     
  252. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019 - (02/04/21)
     
  253. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State - (02/04/21)
     
  254. HIVR4P: US COVID-19 Prevention Network Outlines Goals, Shows Moderna Trial Impact - Mark Mascolini - (02/04/21)
     
  255. HIVR4P: With COVID Here, Mental Health, Money Woes Grow in US Sex- and Gender-Minority Youth - Mark Mascolini - (02/04/21)
     
  256. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019 - (02/03/21)
     
  257. Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents - (02/03/21)
     
  258. REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa - (02/03/21)
     
  259. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA - (02/01/21)
     
  260. How the Search for Covid-19 Treatments Faltered While Vaccines Sped Ahead - (02/01/21)
     
  261. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19 - (02/01/21)
     
  262. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States - (02/01/21)
     
  263. Johnson & Johnson Covid-19 vaccine is 66% effective in global trial, but 85% effective against severe disease, company says - (01/30/21)
     
  264. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination - (01/30/21)
     
  265. ColCORONA: Colchicine Reduces Complications in Outpatient COVID-19 - (01/29/21)
     
  266. Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19 - (01/29/21)
     
  267. COVID-19 infection among people with HIV in New York City: A population-level analysis of linked surveillance data - (01/29/21)
     
  268. UK Doctors Concerned About Delayed Vaccine 2nd Dose Covid: Gap between Pfizer vaccine doses should be halved, say doctors - (01/25/21)
     
  269. COVID Moderna Durability of Response/Delaying 2nd Dose - (01/25/21)
     
  270. COVID-19 will likely be with us forever. Here's how we'll live with it. - (01/25/21)
     
  271. Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines - (01/19/21)
     
  272. SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination - (01/16/21)
     
  273. C.D.C. Warns the New Virus Variant Could Fuel Huge Spikes in Covid Cases - (01/16/21)
     
  274. Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01 - (01/16/21)
     
  275. Dr. Fauci warns Covid variant found in South Africa could pose threat to antibody drugs - (01/16/21)
     
  276. Researchers Discover New Variant of COVID-19 Virus in Columbus, Ohio - (01/16/21)
     
  277. Biden Picks Former F.D.A. Chief to Lead Federal Vaccine Efforts - (01/16/21)
     
  278. J&J COVID Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine - (01/16/21)
     
  279. SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination - (01/16/21)
     
  280. HIV/COVID Statement BHIVA/EACS/GESIDA..... - (01/16/21)
     
  281. J&J COVID Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine - (01/16/21)
     
  282. COVID-19 death in people with HIV: interpret cautiously - Comment - (01/12/21)
     
  283. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera | bioRxiv - (01/12/21)
     
  284. JPM: 'Very soon,' says Johnson & Johnson CEO as world waits for its COVID-19 vaccine data - (01/12/21)
     
  285. CDC/NYS-COVID Vaccine Expands to <65 & Immunocompromised - (01/12/21)
     
  286. NIH COVID Monoclonal Antibody Studies - (01/06/21)
     
  287. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV....CD4 350. CD4 nadir <200 associated with mortality/morbidity - (01/06/21)
     
  288. COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials - (01/06/21)
     
  289. U.K. variant puts spotlight on immunocompromised patients' role in the COVID-19 pandemic - (01/06/21)
     
  290. COVID/Long-Acting 2-Antibody Combination for prevention/Treatment by AstraZeneca - (01/05/21)
     
  291. Discovery of Virus Variant in Colorado and California Alarms Scientists - (01/05/21)
     
  292. How HIV Research Laid the Foundation for Covid Vaccines - (01/05/21)
     
  293. COVID-19 Susceptibility and Outcomes Among People Living With HIV in San Francisco - (12/21/20)
     
  294. Covid-19 / Up to 300,000 Cases Are Traced to Feb. Boston Biotech Conference - (12/14/20)
     
  295. F.D.A. Advisory Panel Gives Green Light to Pfizer Vaccine - (12/14/20)
     
  296. Safety and Efficacy of the [Pfizer] BNT162b2 mRNA Covid-19 Vaccine - (12/14/20)
     
  297. U.S. AstraZeneca vaccine trial will clear confusion on how well it works: U.S. scientist - (12/09/20)
     
  298. FDA Briefing Document Pfizer COVID Vaccine - (12/09/20)
     
  299. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - (12/09/20)
     
  300. Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study - (12/04/20)
     
  301. Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate, 2-Dose Regimen Study - (12/01/20)
     
  302. A High Percentage of People with HIV on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following COVID-19 - (12/01/20)
     
  303. The Virus Won't Stop Evolving When the Vaccine Arrives - (12/01/20)
     
  304. AstraZeneca Vaccine: AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 - (11/23/20)
     
  305. Merck to pay $425M for biotech to get Covid-19 drug, but says manufacturing will be a challenge - (11/23/20)
     
  306. COVID Vaccines/Prevent Infection???? The messenger RNA vaccines and masks - (11/20/20)
     
  307. AASLD: Abnormal liver function tests on admission are associated with increased mortality in hospitalized patients with COVID-19: Results from a large Latin American cohort. (11/19/20)
     
  308. AASLD: SARS-CoV-2 Rewires Lipid and Metabolic Profiles, Posing Heart and Liver Risks - Mark Mascolini (11/19/20)
     
  309. AASLD: Abnormal Liver Tests at COVID Hospitalization Tied to Severe Disease, Death - Mark Mascolini (11/19/20)
     
  310. AASLD: HCC, Decompensation, Alcohol, Tied to Death in Liver Patients With COVID-19 - Mark Mascolini (11/19/20)
     
  311. COVID-19 Diagnoses, Hospitalizations and Mortality among Persons Living with and without Diagnosed HIV Infection in New York State - pdf slides - (11/12/20)
     
  312. Elevated COVID-19 outcomes among persons living with diagnosed HIV infection in New York State: Results from a population-level match of HIV, COVID-19, and hospitalization databases - (11/12/20)
     
  313. NYS Reported today Nov 12 2020: Impact of HIV on COVID Infection, Diagnosis, Hospitalizations, Deaths: COVID Worse Impact Among HIV+ - (11/12/20)
     
  314. Why Pfizer's ultra-cold COVID-19 vaccine will not be at the local pharmacy any time soon - (11/12/20)
     
  315. Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection - FDA News Release - (11/10/20)
     
  316. Biden transition team unveils members of Covid-19 task force - (11/09/20)
     
  317. Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study - (11/09/20)
     
  318. Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate - (11/09/20)
     
  319. Common SARS-CoV-2 Mutation May Be Making COVID-19 More Contagious - (11/06/20)
     
  320. 2 COVID Outpatient Antibody Treatments Report Today - (11/06/20)
     
  321. Brief, Frequent Exposures May Have Led to COVID-19 in Corrections Officer - (11/04/20)
     
  322. U.S. Food and Drug Administration Approves Gilead's Antiviral Veklury® (remdesivir) for Treatment of COVID-19 - (11/04/20)
     
  323. An Open Letter from Merdad Parsey, Chief Medical Officer, Gilead Sciences - (11/04/20)
     
  324. FDA approves Gilead's remdesivir as coronavirus treatment - (11/04/20)
     
  325. Increased COVID Risk/Opioid/Substance Disorders 8-10x Increased Risk - (11/04/20)
     
  326. Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study - (11/04/20)
     
  327. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis - (11/04/20)
     
  328. 2 COVID Outpatient Antibody Treatments Report Today Lilly treatment - SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-1 - (11/04/20)
     
  329. ID Week: Gilead Sciences' Commitment to the COVID-19 Pandemic - (11/03/22)
     
  330. ID Week: Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients - (11/03/22)
     
  331. ID Week: Safety of Remdesivir vs Standard of Care in Patients With Moderate COVID-19 - (11/03/22)
     
  332. ID Week: Baseline Characteristics Associated With Clinical Improvement in Hospitalized Patients With Moderate COVID-19 - (11/03/22)
     
  333. ID Week: Remdesivir vs Standard Care in Patients With Moderate COVID-19 - (11/03/22)
     
  334. ID Week: Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated With Remdesivir - (11/03/22)
     
  335. ID Week: Opioid Clinic Use Doubles After COVID Arrives at Alabama HIV Center - Mark Mascolini (11/02/22)
     
  336. ID Week: Rates of COVID Testing, Diagnosis, and Hospital Admission Higher With HIV - Mark Mascolini (11/02/22)
     
  337. ID Week: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States - increased risk of COVID & had worse outcomes, heroin the worst - (11/02/22)
     
  338. ID Week: Older Age, Comorbidities Predict Hospital Trip for COVID-19 in HIV Group - Mark Mascolini - (10/30/22)
     
  339. ID Week: Increased Diagnosis Acute HIV Through Routine ED Screening & Rapid Linkage to Care & Initiation of HAARTDuring the COVID-19 Pandemic - (10/28/22)
     
  340. ID Week: ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine - (10/28/22)
     
  341. ID Week: Empiric Antibiotics Frequent-But Usually Not Needed-for COVID-19 - Mark Mascolini (10/26/22)
     
  342. GLASGOW: Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago - (10/20/20)
     
  343. GLASGOW: Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study. HIV Drug Therapy/Glasgow 2020 - HIV Raises COVID Death Risk 52% in 47,573-Person UK Study - (10/15/20)
     
  344. GLASGOW: Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study. HIV Drug Therapy/Glasgow 2020 - HIV Raises COVID Death Risk 52% in 47,573-Person UK Study - (10/15/20)
     
  345. GLASGOW: Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago - (10/20/20)
     
  346. Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients - (10/02/20)
     
  347. Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States - (10/02/20)
     
  348. COVID Aerosol Transmission - (09/28/20)
     
  349. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 - (09/28/20)
     
  350. The coronavirus is mutating - does it matter? - (09/28/20)
     
  351. Johnson & Johnson's Vaccine Advances, Sparking Optimism in Race - (09/25/20)
     
  352. Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate - (09/25/20)
     
  353. COVID in Elderly .......Can the science of aging move us forward - (09/23/20)
     
  354. Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV infection in New York City - (09/17/20)
     
  355. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 - (09/17/20)
     
  356. Tiny Antibody Component Highly Effective Against COVID-19 at U of Pitts Mellors team - (09/17/20)
     
  357. Ab8 COVID-19 Drug Breakthrough: Tiny Antibody Component Completely Neutralizes the SARS-CoV-2 Virus - (09/17/20)
     
  358. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry - (09/17/20)
     
  359. COVID J&J Phase 3 Vaccine study Beginning - (08/25/20)
     
  360. SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections - (08/25/20)
     
  361. Hepatitis B and C Virus Considerations in COVID-19 - (08/25/20)
     
  362. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort - (08/25/20)
     
  363. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury - (08/25/20)
     
  364. Characteristics of Liver Tests in COVID-19 Patients - (08/25/20)
     
  365. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis - (08/25/20)
     
  366. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 - (08/25/20)
     
  367. Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics - (08/25/20)
     
  368. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort - (08/25/20)
     
  369. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry - (08/24/20)
     
  370. IAC 2020 Virtual: Characteristics and Predictors of Death among Hospitalized Patients with COVID-19 in Spain - (08/14/20)
     
  371. Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling - (08/10/20)
     
  372. Merck, one of Big Pharma's biggest players, reveals its COVID-19 vaccine and therapy plans - (08/10/20)
     
  373. Merck Bets On a One-Shot Vaccine in Race With Its Faster Rivals - (08/10/20)
     
  374. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement - (05/08/20)
     
  375. NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients - (08/05/20)
     
  376. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing - (08/05/20)
     
  377. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network - (08/05/20)
     
  378. Is COVID-19 Different in People with HIV? - (08/05/20)
     
  379. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy - (08/03/20)
     
  380. Cytokine Blockers May Shield Immune Inflammation Patients From COVID-19 - Mark Mascolini (07/31/20)
     
  381. Early But Not Late Interferon Linked to Lower COVID Mortality in Hubei - Mark Mascolini (07/31/20)
     
  382. COVID antibody Resistance - (07/31/20)
     
  383. Janssen COVID Vaccine Update - (07/31/20)
     
  384. Imperial College advances Covid-19 vaccine into next phase - (07/31/20)
     
  385. Coronavirus research updates: Vaccine candidate protects monkeys from infection - (07/31/20)
     
  386. Gilead Sciences and Satcher Health Leadership Institute at Morehouse School of Medicine Partner to Study Racial Health Inequities Associated with COVID-19 - (07/30/20)
     
  387. Antibodies From 5 People With COVID-19 Show "Exquisite Potency" - Mark Mascolini (07/30/20)
     
  388. COVID-19 More Severe in Hispanics, Blacks in Chicago Safety-Net Hospital - Mark Mascolini (07/30/20)
     
  389. Half With Recent SARS-CoV-2 in SF Hispanic District Have No Symptoms - Mark Mascolini (07/30/20)
     
  390. COVID-19 Severity, Delayed Admission Tied to Longer Viral Shedding - Mark Mascolini (07/30/20)
     
  391. Factors Tied to Clinical Improvement or Death in Phase 3 Remdesivir Trial - Mark Mascolini (07/30/20)
     
  392. Worse Short-Term Memory Predicts Poor COVID Distancing in US - Mark Mascolini (07/29/20)
     
  393. Distancing Tied to 13% Drop in COVID-19 Incidence in 149 Countries - Mark Mascolini (07/29/20)
     
  394. Fewer Baseline ICU Beds Mean Higher Odds of COVID-19 Death - Mark Mascolini (07/29/20)
     
  395. COVID-19 Killing Disproportionate Number of Younger Nonwhites in US - Mark Mascolini (07/29/20)
     
  396. The people with hidden immunity against Covid-19 - t-cells - (07/29/20)
     
  397. Two Symptomatic Hair Stylists Don't Pass COVID-19 to 139 Clients: All Wore Masks (CDC) - (07/29/20)
     
  398. Three Coronavirus Vaccine Developers Report Promising Initial Results - a cautionary note - (07/29/20)
     
  399. Worse Short-Term Memory Predicts Poor COVID Distancing in US - Mark Mascolini (07/29/20)
     
  400. Review Suggests Which COVID-19 Patients Should Get Remdesivir - Mark Mascolini (07/29/20)
     
  401. Tocilizumab Trims Mortality 45% in Intubated COVID-19 Patients - Mark Mascolini (07/29/20)
     
  402. Dexamethasone Cuts Death Rate in COVID-19 Group on Respiratory Support - Mark Mascolini (07/29/20)
     
  403. IAC 2020 Virtual: COVID-19 in the Largest US HIV Cohort - (07/19/20)
     
  404. Moderna's Covid-19 Vaccine Moves to Bigger Study - (07/17/20)
     
  405. IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/16/20)
     
  406. COVID Congress: Baseline Characteristics Associated With Clinical Improvement and Mortality in Hospitalized Patients With Severe COVID-19 Treated With Remdesivir - (07/16/20)
     
  407. COVID Congress: Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care - (07/16/20)
     
  408. GILEAD SCIENCES STATEMENT ON THE INITIATION OF CLINICAL TESTING OF AN INHALED SOLUTION OF REMDESIVIR FOR POTENTIAL OUTPATIENT TREATMENT OF COVID-19 - (07/16/20)
     
  409. European Commission Grants Conditional Marketing Authorization for Gilead's Veklury® (remdesivir) for the Treatment of COVID-19 - (07/16/20)
     
  410. IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/15/20)
     
  411. IAC 2020 Virtual: With COVID Here, 90% of Australian MSM Have Less Sex, 40% Stop PrEP - Mark Mascolini (07/15/20)
     
  412. IAC 2020 Virtual: HCV Drugs for COVID-19? Three Small Studies Have Positive Hints - Mark Mascolini (07/15/20)
     
  413. IAC 2020 Virtual: Racial Disparities, Communal Living in Boston COVID-19 Patients With HIV - Mark Mascolini (07/15/20)
     
  414. IAC 2020 Virtual: Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center - (07/13/20)
     
  415. Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2 - (07/02/20)
     
  416. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report - (07/02/20)
     
  417. ViiV Healthcare announces grantees selected as part of 3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic - (07/02/20)
     
  418. ViiV Healthcare announces grantees selected as part of 3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic - PRESS RELEASE - (06/30/20)
     
  419. Remdesivir Pricing - - An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences - press release - (06/30/20)
     
  420. Immune system and COVID - (06/29/20)
     
  421. Covid-19 and People with HIV Infection: Outcomes for Hospitalized Patients in New York City - (06/29/20)
     
  422. Mutated coronavirus shows significant boost in infectivity - (06/29/20)
     
  423. Neutralizing Antibodies Shortly After COVID-19 Recovery: Scant But Strong - Mark Mascolini (06/24/20)
     
  424. Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019 - (06/24/20)
     
  425. SARS-CoV-2 Antibody Cocktail Prevents Rapid Emergence of Antibody Resistance - Mark Mascolini (06/24/20)
     
  426. Risk of Increased Physical Inactivity During COVID 19 Outbreak in Older People: A Call for Actions - Editorial - (06/22/20)
     
  427. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study - (06/22/20)
     
  428. Where New Yorkers Moved to Escape Coronavirus The Richest Neighborhoods Emptied Out Most as Coronavirus Hit New York City - (06/22/20)
     
  429. Still Antibodies Might Protect - You May Have Antibodies After Coronavirus Infection. But Not for Long. - (06/22/20)
     
  430. Chinese study: Antibodies in COVID-19 patients fade quickly - (06/22/20)
     
  431. Gilead to begin human trials for the inhaled version of coronavirus drug remdesivir - An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences - (06/22/20)
     
  432. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study - (06/19/20)
     
  433. GILEAD SCIENCES STATEMENT ON PHASE 2/3 CLINICAL TRIAL OF REMDESIVIR IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19 - (06/18/20)
     
  434. Remdesivir by Gilead Sciences: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of Treatment - (06/17/20)
     
  435. COVID-19: Steroid Lowered Mortality / Rural America / Potential Drug-Drug Interaction - (06/17/20)
     
  436. Florida sees a record 2,783 daily coronavirus cases as state total hits 80,000 - (06/17/20)
     
  437. expert reaction to the RECOVERY trial reporting that dexamethasone reduces death by up to one third in hospitalised COVID-19 patients with severe respiratory complications - (06/17/20)
     
  438. Coronavirus breakthrough: dexamethasone is first drug shown to save lives - (06/17/20)
     
  439. NYS sees lowest amount of COVID-19 deaths since crisis began, New Yorkers must stay disciplined - (06/15/20)
     
  440. J&J Speeds Up Covid Vaccine Plans in Sprint Against Second Wave - (06/15/20)
     
  441. Greater risk of post-vaccination breakthrough severe COVID-19 illness in people with HIV and CD4 <350 - (06/13/22)
     
  442. High rates of 30-day mortality in patients with cirrhosis and COVID-19 - (06/12/20)
     
  443. Small Impact of Warmer Temperatures on SARS-CoV-2 Rate in US - Mark Mascolini (06/10/20)
     
  444. WHO Sparks Fresh Debate on Role of Covid's Silent Spreaders - WHO Changes "rare" position - (06/09/20)
     
  445. WHO: Asymptomatic COVID-19 spread deemed 'rare' ("much less likely") - (06/09/20)
     
  446. FDA - Independent Evaluations of COVID-19 Serological Tests - (06/08/20)
     
  447. Why Aren't People Living with HIV at Higher Risk for Developing Severe Coronavirus Disease 2019 (COVID-19)? - (06/05/20)
     
  448. 2 Papers About Drug Therapy (hydroxychloroquine) in COVID-19 Retracted From Prestigious Journals - (06/05/20)
     
  449. Bars, barbers, and barbecues: COVID-19 risk as daily activities resume. Food Takeout Ranked as Low Risk - Mark Mascolini (06/05/20)
     
  450. TWO RETRACTIONS - (06/05/20)
     
  451. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area - (06/03/20)
     
  452. COVID-19 in people with HIV - Comment on Madrid Data - (06/03/20)
     
  453. Clinical features and outcome of HIV/SARS-CoV-2 co-infected patients in the Bronx, New York City - (06/03/20)
     
  454. BHIVA, DAIG, EACS, GESIDA & Polish Scientific AIDS Society Statement on risk of COVID-19 for people living with HIV (PLWH) - (06/03/20)
     
  455. Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions - (06/03/20)
     
  456. New York City & USA Coronavirus Map and Case Count - (06/03/20)
     
  457. New Redemsivir Study Results: moderate disease. Gilead Press Statements Today June 1 2020 - (06/01/20)
     
  458. New Merck COVID Efforts-2 Vaccines+Antiviral Drug EIDD-2801; Acquisition & Collaborations - (05/26/20)
     
  459. Sunlight Inactivates COVID Virus and Lowers New Case Rate - Mark Mascolini (05/26/20)
     
  460. Treating Mild Coronavirus Cases Could Help Save Everyone - Opinion - (05/26/20)
     
  461. Low CD4s and CD8s-But Not Viral Genetics-Predict COVID-19 Progression - Mark Mascolini (05/26/20)
     
  462. J&J COVID Vaccine New Data Published: DNA vaccine protection against SARS-CoV-2 in rhesus macaques - (05/21/20)
     
  463. Blacks/African Americans are 5 Times More Likely to Develop COVID-19, COPD/heart disease>65 also associated: Spatial Modeling of New York City ZIP Code-level Testing Results - (05/21/20)
     
  464. More than a third of residents in some poor N.Y.C. areas tested positive for virus antibodies. - (05/21/20)
     
  465. Two Studies Chart Robust CD4 T-cell Responses to COVID-19 Virus - Mark Mascolini (05/19/20)
     
  466. Severe Covid-19 - therapies - (05/19/20)
     
  467. Estimated 35 Million US COVID-19 Cases Without Social Distancing - Mark Mascolini (05/19/20)
     
  468. Gilead Drug Remdesivir: Rare Example of Foresight in the Pandemic - (05/19/20)
     
  469. COVID & Genetics - CCR5 Leronlimab therapy checked COVID-19 inflammation - (05/19/20)
     
  470. Monitoring COVID-19 from hospital to home: First wearable device continuously tracks key symptoms - (05/15/20)
     
  471. NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19 - (05/15/20)
     
  472. HIV+ & COVID Experience-Italy - (05/15/20)
     
  473. NY Case-Control Study Hints at Similar COVID-19 Outcomes With or Without HIV - Mark Mascolini (05/15/20)
     
  474. COVID/Children 85 Cases in NYC Mysterious Syndrome (100 now) - (05/15/20)
     
  475. COVID/Organ Affects-Damages - (05/14/20)
     
  476. ACE or ARB Drugs Do Not Boost Risk of COVID-19 or Flu - Mark Mascolini (05/14/20)
     
  477. Coronavirus may never go away, World Health Organization warns - (05/14/20)
     
  478. NY Case-Control Study Hints at Similar COVID-19 Outcomes With or Without HIV - Mark Mascolini (05/14/20)
     
  479. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients - (05/14/20)
     
  480. ACE or ARB Drugs Do Not Boost Risk of COVID-19 or Flu - Mark Mascolini (05/13/20)
     
  481. Voluntary Licensing Agreements for Remdesivir Gilead Announcement - (05/13/20)
     
  482. Two US Studies Link Social Measures and Masks to COVID Control - Mark Mascolini (05/11/20)
     
  483. COVID Virus a Genetic Cousin of Scaly Mammal Coronavirus - Mark Mascolini (05/11/20)
     
  484. FDA EUA Authorized Serology Test Performance (05/11/20)
     
  485. Hold on Antibody Testing: 'The FDA Has Done Us a Disservice' (05/11/20)
     
  486. Moderna COVID Vaccine - FDA clearance to proceed with Phase 2 study (05/11/20)
     
  487. Study Finds Nearly Everyone Who Recovers From COVID-19 Makes Coronavirus Antibodies (05/11/20)
     
  488. FDA News Release - Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens (05/11/20)
     
  489. Two US Studies Link Social Measures and Masks to COVID Control - Mark Mascolini (05/11/20)
     
  490. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate (05/07/20)
     
  491. Pfizer, NYU working on innovative coronavirus vaccine that could be ready by end of summer (05/07/20)
     
  492. Controversy Over SARS-CoV-2 Mutation and What It Means (05/07/20)
     
  493. New Cases Increase in Certain States as NY declines - Models Project Sharp Rise in Deaths as States Reopen (05/07/20)
     
  494. SARS-CoV-2 Mutant Took Over as Pandemic Erupted-Probably Giving Virus Advantages (05/07/20)
     
  495. Gilead's remdesivir has seen success against the coronavirus. Now the company has to make enough to supply the world (05/07/20)
     
  496. Inflammatory Syndrome in NYC/European Kids Possibly Related to COVID-19 - Mark Mascolini (05/07/20)
     
  497. FDA Letter authorizing the emergency use of remdesivir for treatment of COVID-19 (05/07/20)
     
  498. Gilead Drug Is Cleared for Emergency Use by FDA, Trump Says (05/07/20)
     
  499. Famed HIV researcher on the race to find a COVID-19 treatment (05/07/20)
     
  500. What Is 'Covid Toe'? Maybe a Strange Sign of Coronavirus Infection (05/06/20)
     
  501. FDA gives approval to Roche coronavirus antibody test that claims 100% accuracy (05/06/20)
     
  502. Dr Birx COVID Projections (05/06/20)
     
  503. Dr. Birx: Michigan protests 'devastatingly worrisome'; vaccine 'possible' by January (05/05/20)
     
  504. U.S. Could See 'Persistent Spread' of COVID-19 Through Summer, Former FDA Chief Says (05/05/20)
     
  505. Gilead CEO says remdesivir will be available to patients this week: 'We've donated the entire supply' (05/05/20)
     
  506. Redemsivir (05/04/20)
     
  507. Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark (05/04/20)
     
  508. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients (05/04/20)
     
  509. US Experts Predict Waves of COVID-19 Lasting Into 2022 - Mark Mascolini (05/04/20)
     
  510. Gilead announcement: GILEAD'S INVESTIGATIONAL ANTIVIRAL REMDESIVIR RECEIVES U.S. FOOD AND DRUG ADMINISTRATION EMERGENCY USE AUTHORIZATION FOR THE TREATMENT OF COVID-19 (05/04/20)
     
  511. FDA Letter authorizing the emergency use of remdesivir for treatment of COVID-19 (05/04/20)
     
  512. Gilead Drug Is Cleared for Emergency Use by FDA, Trump Says (05/04/20)
     
  513. Famed HIV researcher on the race to find a COVID-19 treatment (05/04/20)
     
  514. Wisconsin April Primary Election Did Not Boost COVID-19 Cases - Mark Mascolini (05/01/20)
     
  515. HHS Interim Guidance for COVID-19 and Persons with HIV - (05/01/20)
     
  516. In Race for a Coronavirus Vaccine, an Oxford Group Leaps Ahead - (04/30/20)
     
  517. J&J Letter to HIV Community - (04/30/20)
     
  518. The Time for Universal Masking of the Public for Coronavirus Disease 2019 Is Now. Monica Gandhi & Diane Havlir - (04/30/20)
     
  519. Redemsivir "standard of care/authorized emergency use likely" - (04/30/20)
     
  520. Seniors With COVID-19 Show Unusual Symptoms, Doctors Say - (04/30/20)
     
  521. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 - (04/30/20)
     
  522. Some Coronaviruses Can Reinfect Same Person Quickly: Will That Happen With SARS-CoV-2? - (04/30/20)
     
  523. Global coronavirus death toll could be 60% higher than reported - Free to read - (04/30/20)
     
  524. COVID-19: Special Considerations for People Living with HIV - (04/30/20)
     
  525. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 - (04/30/20)
     
  526. Seniors With COVID-19 Show Unusual Symptoms, Doctors Say - (04/29/20)
     
  527. HIV & COVID-19 - (04/29/20)
     
  528. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 - (04/29/20)
     
  529. SF COVID-19 & HIV Town Hall - (04/29/20)
     
  530. COVID-19 Mortality 30% in Intubated US Group-Well Below Prior Reports - Mark Mascolini (04/29/20)
     
  531. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 - (04/29/20)
     
  532. A mysterious blood-clotting complication is killing coronavirus patients - (04/27/20)
     
  533. ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients - (04/27/20)
     
  534. Plea for multitargeted interventions for severe COVID-19 - (04/27/20)
     
  535. US Has Not Turned Corner in Shutting Down Coronavirus Nationwide - Mark Mascolini (04/27/20)
     
  536. Three US Groups Report Stroke in Middle-Aged With COVID-19 - Mark Mascolini - (04/27/20)
     
  537. Anorexia Leads GI Complaints in Multicenter US Group With COVID-19 - (04/27/20)
     
  538. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems - (04/27/20)
     
  539. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area - (04/27/20)
     
  540. COVID-19 in Patients With HIV - new study, database - (04/27/20)
     
  541. ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic - PRESS RELEASE - (04/27/20)
     
  542. COVID-19 Virus Remains Infectious Up to 16 Hours in Air - Mark Mascolini - (04/24/20)
     
  543. NIAID strategic plan details COVID-19 research priorities - (04/24/20)
     
  544. COVID-19 Virus Remains Infectious Up to 16 Hours in Air - Mark Mascolini - (04/24/20)
     
  545. COVID-19 Virus Remains Infectious Up to 16 Hours in Air - Mark Mascolini - (04/24/20)
     
  546. Over 20% Worldwide Have Conditions That Raise Risk of Severe COVID-19 - Mark Mascolini - (04/24/20)
     
  547. Remdesivir Trial/Bronx NY - (04/24/20)
     
  548. Avid Anti-COVID Hand Cleaning May Spark Eczema Outbreak - Mark Mascolini - (04/24/20)
     
  549. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 - (04/24/20)
     
  550. COVID-19: Special Considerations for People Living with HIV - (04/24/20)
     
  551. Severe vs Milder COVID-19 Tied to 6-Fold Higher Risk of Acute Heart Injury - (04/24/20)
     
  552. Can a Simple Drug-Store Device Keep People From Slipping Into Severe COVID? - (04/23/20)
     
  553. Antiviral remdesivir prevents disease progression in monkeys with COVID-19 - (04/23/20)
     
  554. Clinical Characteristics of Covid-19 in New York City - (04/23/20)
     
  555. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic - (04/23/20)
     
  556. IDSA's COVID-19 Treatment Guidelines Highlight Difficulty of "Don't Just Do Something, Stand There" - using unapproved COVID treatments - (04/23/20)
     
  557. PrEP at CROI 2020 - (04/23/20)
     
  558. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data - (04/22/20)
     
  559. Remdesivir Trial in Bronx, NY - (04/22/20)
     
  560. An Overlooked, Possibly Fatal Coronavirus Crisis: A Dire Need for Kidney Dialysis - (04/22/20)
     
  561. ACEIs and ARBs for Hypertension Tied to Lower Death Risk With COVID-19 - (04/22/20)
     
  562. Studies Stoke Concern About Coronavirus Contagion Through Air via Speech....correction - (04/22/20)
     
  563. IDSA release recommendations on reopening economy: - (04/22/20)
     
  564. Corticosteroids for Coronavirus Tied to Longer Hospital Stay, Doubled Death Risk - Mark Mascolini - (04/22/20)
     
  565. New COVID Vaccine Ready By Autumn Maybe - Cambridge Researchers - (04/22/20)
     
  566. Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment - (04/22/20)
     
  567. Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS) - (04/22/20)
     
  568. Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts - (04/21/20)
     
  569. COVID-19 in patients with HIV: clinical case series - (04/21/20)
     
  570. Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment - (04/21/20)
     
  571. Airborne transmission of SARS-CoV-2: The world should face the reality - (04/21/20)
     
  572. Studies Stoke Concern About Coronavirus Contagion Through Air via Speech - Mark Mascolini - (04/21/20)
     
  573. HIV/Infectious Disease Providers Launch CURE HIV-COVID Registry - (04/21/20)
     
  574. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study - (04/21/20)
     
  575. COVID-19: Special Considerations for People Living with HIV Updated (IDSA, HIVMA): April 4, 2020 - (04/21/20)
     
  576. Frontline lessons learned and measures implemented for people living with HIV - (04/21/20)
     
  577. One in Three Household Members Picks Up Virus From Person With COVID-19 - Mark Mascolini (04/21/20)
     
  578. Gilead Announces $20 Million Philanthropic Fund to Support Nonprofit Organizations Impacted by the COVID-19 Crisis - (04/21/20)
     
  579. J&J statement: Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2: - (04/20/20)
     
  580. Atazanavir In Vitro vs COVID - A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 - (04/20/20)
     
  581. Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 - (04/17/20)
     
  582. HIV/Infectious Disease Providers Launch CURE HIV-COVID Registry - (04/17/20)
     
  583. HRSA Ryan White Information: Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions - (04/17/20)
     
  584. TDF/FTC/TAF COVID Inhibitors - (04/17/20)
     
  585. Oncology Practice During the COVID-19 Pandemic (new Care & Labs Models needed for HIV) - (04/17/20)
     
  586. SARS-CoV-2 Carrying Time Averages 4 Weeks in Inpatients - Mark Mascolini (04/17/20)
     
  587. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 - (04/17/20)
     
  588. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic - (04/17/20)
     
  589. NIH Vaccine Chief Optimistic on Prospects for SARS-CoV-2 Vaccine - (04/17/20)
     
  590. COVID-19 Chloroquine Study Stops Because of Abnormal Heart Rhythms, Deaths - Mark Mascolini (04/17/20)
     
  591. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 - (04/17/20)
     
  592. The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection - (04/16/20)
     
  593. Nationwide US Data Hint at Leveling Daily Case Rate for COVID-19 - (04/16/20)
     
  594. Gilead CEO Comments/Remdesivir Compassionate Access Results - (04/16/20)
     
  595. Available Weapons to Fight COVID-19 - (04/16/20)
     
  596. Clinical and virological data of the first cases of COVID-19 in Europe: a case series - (04/16/20)
     
  597. Company Statements Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials - (04/16/20)
     
  598. WHO Report: HIV+ COVID Responses - (04/16/20)
     
  599. WHO Report: HIV+ COVID Responses - (04/14/20)
     
  600. HIV+ & COVID - response to this virus by HIV+ in China - (04/14/20)
     
  601. Hydroxychloroquine Update For April 6 - (04/14/20)
     
  602. Remdesivir- An Update from Gilead Chairman & CEO Daniel O'Day - (04/14/20)
     
  603. Special Report: How Korea Trounced U.S. in Race to Test People for Coronavirus - (04/14/20)
     
  604. The Lost Month: How a Failure to Test Blinded the U.S. to Covid-19 - (04/14/20)
     
  605. Convalescent Plasma to Treat COVID-19 - Possibilities and Challenges - (04/14/20)
     
  606. Rationing Care, Ventilators, Life Saving Measures in COVID-19 - (04/14/20)
     
  607. Genomic Study Points to Natural Origin of COVID-19 - (04/14/20)
     
  608. Long Island has 6,649 cases with both counties combined. - (04/14/20)
     
  609. The COVID Tracking Project - (04/14/20)
     
  610. Coronavirus Disease (COVID-19) - Statistics and Research - (04/13/20)
     
  611. J&J COVID Vaccine: "We are counting on a 10 euro vaccine against coronavirus" - (04/06/20)
     
  612. Letter from Gilead: Message from Amy Flood: Supporting our friends and partners - (04/06/20)
     
  613. COVID & HIV+ China Report Preliminary Data, How do PLWH Fare? - (04/06/20)
     
  614. Letter from Gilead: Message from Amy Flood: Supporting our friends and partners - (04/02/20)
     
  615. Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation - (03/26/20)
     
  616. Britain's Prince Charles tests positive for COVID-19; Camilla negative - (03/26/20)
     
  617. Could the summer bring an end to COVID-19? - (03/26/20)
     
  618. A Case of Severe Hydroxychloroquine-Induced Retinal Toxicity in a Patient with Recent Onset of Renal Impairment: A Review of the Literature on the Use of Hydroxychloroquine in Renal Impairment - (03/26/20)
     
  619. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial - (03/26/20)
     
  620. HYDROXYCHLOROQUINE (PLAQUENIL) CARDIOTOXICITY: AN UNCOMMON COMPLICATION OF A COMMON MEDICATION - (03/26/20)
     
  621. Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation - (03/26/20)
     
  622. Investigational COVID-19 Convalescent Plasma - Emergency INDs - (03/24/20)
     
  623. NY Doc Who Survived Ebola: This Is Why I Fear COVID-19 - (03/24/20)
     
  624. Should patients with COVID-19 avoid ibuprofen or RAAS antagonists? - (03/24/20)
     
  625. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 - (03/24/20)
     
  626. Investigational COVID-19 Convalescent Plasma - Emergency INDs - (03/24/20)
     
  627. States work to limit prescriptions of potential coronavirus drugs - (03/24/20)
     
  628. AbbVie waives all worldwide restrictions on making generic copies of its Kaletra HIV pill - (03/24/20)
     
  629. Jails in Crisis: Tri-State Inmates Released to Manage Rapid COVID-19 Spread - (03/24/20)
     
  630. New York corona cases surge; Javits Center to house temporary hospitals - (03/24/20)
     
  631. COVID DDIs - Liverpool - (03/24/20)
     
  632. 'I'm going to keep pushing.' Anthony Fauci tries to make the White House listen to facts of the pandemic - (03/24/20)
     
  633. Information from LabCorp about Coronavirus Disease 2019 (COVID-19) - (03/24/20)
     
  634. Increasing number of biopharma drugs target COVID-19 as virus spreads - (03/24/20)
     
  635. Promotion of Telehealth Services Among AIDS Institute-funded Contractors to Mitigate Spread of COVID-19 - (03/24/20)
     
  636. How Long Does Coronavirus Survive in the Air and on Surfaces? - (03/24/20)
     
  637. ViiV - Our Response to COVID-19 - (03/24/20)
     
  638. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line - (03/24/20)
     
  639. Gilead/Continued Supply of HIV Medicine During the Novel Coronavirus Outbreak - (03/24/20)
     
  640. Interim Guidance on Management of Coronavirus Disease 2019 (COVID-19) in Correctional and Detention Facilities - (03/24/20)
     
  641. CDC - HIV and COVID-19 - (03/24/20)
     
  642. Interim Guidance for COVID-19 and Persons with HIV - (03/24/20)
     
  643. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? - (03/24/20)
     
  644. The Coronavirus Conundrum: ACE2 and Hypertension Edition - (03/24/20)
     
  645. Army plans to turn NYC hotel, dorm rooms into coronavirus hospitals - (03/24/20)
     
  646. NYS Drafting Guidelines on Possible Ventilator Rationing; U.S. Coronavirus Cases Jump; FDA Approves Rapid Test - (03/24/20)
     
  647. FDA authorizes first rapid, 'point of care' coronavirus test - (03/23/20)
     
  648. Famed AIDS Researcher Is Racing to Find a Coronavirus Treatment - (03/23/20)
     
  649. 'Who lives and who dies': In worst-case coronavirus scenario, ethics guide choices on who gets care - (03/23/20)
     
  650. Hospitals Stockpile Drug Trump Says Could Treat Covid-19 - (03/23/20)
     
  651. New York City Region Is Now an Epicenter of the Coronavirus Pandemic - (03/23/20)
     
  652. Hydroxychloroquine....'They could work': Coronavirus drug trials to begin in N.Y. state, Cuomo says - (03/23/20)
     
  653. Company Statements Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials - (03/23/20)
     
  654. COVID-19 World Map Forecasting - (03/23/20)
     
  655. Launch of a European clinical trial against COVID-19 - (03/23/20)
     
  656. New York City Region Is Now an Epicenter of the Coronavirus Pandemic - (03/23/20)